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Rose-Minke Schure,a,b Lotte H. Hendrikx,c Lia G. H. de Rond,a Kemal O¨ztürk,a Elisabeth A. M. Sanders,b Guy A. M. Berbers,a
and Anne-Marie Buismana
Laboratory for Infectious Disease and Perinatal Screening, Center for Infectious Diseases Control, National Institute for Public Health, Bilthoven, The Netherlandsa;
Department of Pediatric Immunology and Infectious Diseases, UMC, Utrecht, The Netherlandsb; and Department of Pediatrics, Free University of Amsterdam (VUMC),
Amsterdam, The Netherlandsc
Immunization with acellular pertussis vaccine (aP) induces higher specific antibody levels and fewer adverse reactions than does
immunization with the whole-cell vaccine (wP). However, antibody levels in infants induced by both types of pertussis vaccines
wane already after 1 year. Therefore, long-term T-cell responses upon vaccinationmight play a role in protection against pertus-
sis. In a cross-sectional study (ISRCTN65428640), we investigated T-helper (Th) cell immune responses in wP- or aP-vaccinated
children before and after an aP low-dose or high-dose preschool booster at 4 years of age in The Netherlands. T cells were stimu-
lated with pertussis vaccine antigens. The numbers of gamma interferon-producing cells and Th1, Th2, Th17, and interleukin-10
(IL-10) cytokine concentrations were determined. In addition, pertussis-specific IgE levels were measured in plasma. Children
being vaccinated with aP vaccinations at 2, 3, 4, and 11 months of age still showed higher pertussis-specific T-cell responses at 4
years of age than did wP-vaccinated children. These T-cell responses failed to show a typical increase in cytokine production af-
ter a fifth aP vaccination but remained high after a low-dose booster and seemed to decline even after a high-dose booster. Im-
portantly, elevated IgE levels were induced after this booster vaccination. In contrast, wP-vaccinated children had only low pre-
booster T-cell responses, and these children showed a clear postbooster T-cell memory response even after a low-dose booster
vaccine. Four high-dose aP vaccinations in infancy induce high T-cell responses still present even 3 years after vaccination and
enhanced IgE responses after preschool booster vaccination. Therefore, studies of changes in vaccine dosage, timing of pertussis
(booster) vaccinations, and the possible association with local side effects are necessary.
Recently, during a large pertussis outbreak in California 10 in-fants have died (19), and 9,154 cases of whooping cough have
been reported by the California Department of Public Health (4).
Already in the 1990s, many developed countries replaced the
whole-cell pertussis component (wP) with the acellular pertussis
component (aP) in the DTP-IPV-Hib combination vaccine in or-
der to achieve higher antigen-specific antibody levels and fewer
side effects. This, however, did not stop the reemergence of per-
tussis in these countries (8, 38, 39). The high incidence of pertussis
worldwide can be (partly) explained by adaptation of the circulat-
ing bacterial strains to vaccine pressure as well as waning immu-
nity after vaccination and natural infection (2, 27).
In TheNetherlands, wP vaccines have been used since the early
1950s, resulting in a decline of pertussis disease. Despite a high
vaccination coverage, the incidence of pertussis increased
again after 1996, and for this reason, an aP preschool booster
vaccination (aP) was introduced at 4 years of age in 2001. From
2005 onwards, the infant wP vaccine component administered
at 2, 3, 4, and 11 months of age has also been replaced by the aP
vaccine.
Pertussis-specific antibody levels are induced by vaccination
and natural infection and protect against disease; however, these
levels decline very rapidly after vaccination (9, 13). Several studies
have shown that protection against disease also relies on T-helper
(Th) cells, as well as antibodies (7, 26). Multiple Th cell lineages
may be involved, like the Th1, Th2, and Th17 cells, and each lin-
eage is characterized by specific cytokine repertoires (6).However,
the induction of long-term T-cell memory responses and the rel-
ative contribution of each Th cell lineage upon vaccination are
largely unknown. Previous studies have shown that aPmay lead to
Th2 cytokine repertoires in infants and children, whereas wP
rather primes for Th1 immune responses (1, 23). The aP vaccines
consist of some purified pertussis proteins that may differ from
wP vaccines in the induction of Th cell responses, which include
many other biological components. Information about T-cell im-
munity after pertussis vaccination and comparison between wP-
and aP-primed infants is scarce. Moreover, Th2 responses might
be associated with atopic reactions (31), and pertussis-specific IgE
has been found after aP vaccinations in infants (28). The aim of
this study is to assess the Th1, Th2, and Th17 as well as inter-
leukin-10 (IL-10) cytokine responses to pertussis vaccine anti-
gens in children 4 years of age who received either a low-dose or
a high-dose antigen aP preschool booster vaccination. We
compared groups of children who have been primed either by
wP or by aP in infancy. Apart from T-cell kinetics, also pertus-
sis antigen-specific IgE responses in these groups of children
are studied.
MATERIALS AND METHODS
Subjects and studydesign. In this study, a cohort of children 4 years of age
forms a subset of a cross-sectional observational study in TheNetherlands
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(ISRCTN65428640) performed from 2007 (wP-primed children) on-
wards until 2008 (aP-primed children), which aimed to investigate per-
tussis-specific immunity in children 3 to 9 years of age. The pertussis
vaccine-specific IgG antibody responses in these 4-year-old children have
been published previously (13). Now, we evaluated T-cell immune re-
sponses in a randomly selected subset of these children (n  92). As
previously described (13), we divided the children into 8 different groups,
according to (i) the vaccination history (wP or aP priming), (ii) the type of
preschool booster vaccine (low-dose or high-dose aP), and (iii) time of
blood sampling, i.e., before the booster or 10 or 28 days after the booster
(Fig. 1). This study was conducted according to the Declaration of Hel-
sinki, Good Clinical Practice Guidelines, with the approval of the relevant
ethics review committee. Written informed consent was obtained from
either parents or legal representatives.
Vaccines. All wP-primed children had received the DTwP-IPV-Hib
(NVI, Bilthoven, The Netherlands) vaccine and all aP-primed children
had received the DTaP-IPV-Hib (Infanrix-IPV-Hib; GlaxoSmithKline
Biologicals S.A., Rixensart, Belgium) vaccine at 2, 3, 4, and 11 months of
age according to the Dutch National Immunization Programme (NIP).
The wP vaccine contained, among other bacterial proteins, about 0.16g
pertussis toxin (PT), 2.6 g filamentous hemagglutinin (FHA), and an
unknown amount of pertactin (Prn), while the aP vaccine contained 25
g PT, 25 g FHA, and 8 g Prn. During the inclusion period of this
study, children received randomly either a low-dose or a high-dose pre-
school booster vaccine due to a shortage in supply of the vaccine. There-
fore, we included children who had received a low-dose booster vaccine,
Triaxis (Sanofi Pasteur, Lille, France), containing 2.5 g PT, 5 g FHA, 3
g Prn, and 5 g fimbria types 2 and 3, or a high-dose booster vaccine,
Infanrix, in wP- and aP-primed children, at 28 days postbooster. At 10
days postbooster, we were able to include only wP-primed children who
received a low-dose booster and aP-primed children who received a high-
dose booster, because the booster vaccine in the NIP had switched during
the period of our study.
T-cell stimulation. Peripheral blood mononuclear cells (PBMCs)
were isolated from blood as described earlier and frozen (3). After thaw-
ing, 3.0 105 viable cells per well were cultured in AIMVmedium (Gibco
Invitrogen, Grand Island, NY) containing 5% human AB serum (Harlan
Laboratories, Leicestershire, United Kingdom) (AIMV) for 5 days at
37°C and 5% CO2 in 96-well round-bottomed culture plates (Greiner,
Invitrogen, Breda, The Netherlands) and stimulated in triplicate with 2
g/ml inactivated PT, FHA (Kaketsuken, Kumamoto, Japan; endotoxin
content,  1.17 endotoxin units [EU]/ml), 4 g/ml of recombinant Prn
(22), and 5 g/ml pokeweed mitogen (Sigma Chemicals, St. Louis, MO)
as a positive control. Nonstimulated (NS) cells served as negative controls.
The purified PT and FHA batches were heat inactivated by incubation for
10min at 80°C. The batch of Prnwas controlled for endotoxin contents by
use of the Limulus amebocyte lysate assay (17). One batch of each antigen
was used for the whole study. In preliminary experiments, we determined
the optimal pertussis antigen concentrations for cell stimulation and the
culture period needed to measure optimal numbers of gamma interferon
(IFN-)-producing cells. After both 1 day and 5 days of stimulation, cul-
ture supernatants were collected and stored at80°C to be able to mea-
sure early and late cytokine responses. T-cell responses were measured in
culture supernatants, and 5 to 13 samples in all groups indicated in Fig. 1
were analyzed.
IFN- ELISpot assay. Enzyme-linked immunosorbent spot
(ELISpot) plates (MSIP4510; Millipore, Danvers, MA) prewetted with
70% ethanol were coated overnight with 5 g/ml anti-human IFN-
(Mabtech, Nacka Strand, Sweden) in phosphate-buffered saline (PBS).
After three washes with PBS and blocking the plates for 2 h with AIMV,
1.4 105 stimulated cells perwell were serially diluted 2-fold and cultured
for 18 h at 37°C and 5%CO2. After fourwashes with PBS-0.05%Tween 20
(PBST) (washed) and cell lysis with water, plates were incubated with 1
g/ml anti-human IFN- (Mabtech) for 2 h in combination with perox-
idase-labeled extravidin (Sigma) for 1 h. Spots were developed as de-
scribed previously (14).
Multiplex bead-based immunoassay for cytokines. The cytokines
IFN-, tumor necrosis factor alpha (TNF-), IL-5, IL-13, IL-17, and IL-10
were determined in supernatants after 5 days, and IL-2wasmeasured after
1 day of stimulation by commercial multiplex bead-based immunoassay
kits according to the manufacturer’s instructions (Bio-Rad Laboratories,
Hercules, CA). All samples presented in this study have been stored just
for a few months before testing and have been randomly divided over the
different tests to avoid interassay variation between the samples.Measure-
ments were performed with a Bio-Plex 200 in combination with Bio-Plex
Manager software (Bio-Rad).
Bordetella pertussis-specific IgE. Plasma samples were depleted of
IgG by adding Gulsorb (1:10, vol/vol) (Meridian Bioscience Inc., Cincin-
nati, OH). Afterwards, the concentration of pertussis-specific IgE was
measured using goat anti-human IgE-phycoerythrin (PE) (Epsilon;
FIG 1 Different groups of children were used in this study: wP-primed and aP-primed children at 2, 3, 4, and 11 months of age received a booster at 4 years of
age with either a low-dose or a high-dose vaccine. Groups of childrenwere studied before booster and at 10 and 28 days after booster. The numbers of individuals
used varied in the different assays as indicated.
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Fisher Scientific) in a multiplex bead-based assay as described previously
(15, 37). IgE responses were measured in 16 to 52 plasma samples of all
groups presented in Fig. 1.
Definitions, datapresentation, and statistical analysis.All individual
data or geometric mean (GM) values and 95% confidence intervals per
group were presented. Background values of negative-control cells were
deducted from each sample. Significant differences between groups (P
0.05) were determined as indicated.
RESULTS
Induction of T-cell cytokines in wP- and aP-primed children in
infancy. The concentrations of the T-cell cytokines TNF-,
IFN-, IL-5, IL-17, and IL-10 specific for the pertussis proteins
PT, FHA, and Prn in PBMCs of aP- and wP-primed children
before and 28 days after a high-dose aP preschool booster are
illustrated in Fig. 2. At 4 years of age, 3 years after four aP
FIG 2 Concentrations of Th1 (TNF- and IFN-), Th2 (IL-5), Th17 (IL-17), and IL-10 cytokines in supernatants of PBMCs of wP- (gray bars) and aP-primed
(white bars) children specific for the pertussis proteins PT, FHA, and Prn. Bars represent GMs and 95% confidence intervals of data prebooster and at 28 days
after booster vaccination with a high-dose aP vaccine. Groups consisted of 13 individuals before booster vaccination and 5 to 8 persons at 28 days after booster
vaccination. *, significantly increased values in aP-primed children compared to wP-primed children; #, significant increase at 28 days after booster
vaccination compared to prebooster values in wP-primed children; ‡, significant decrease at 28 days after booster compared to prebooster values in
aP-primed children.
T-Cell Responses to Preschool aP Pertussis Vaccine
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vaccinations in the first year of life, most prebooster T-cell
cytokine levels specific for all three pertussis proteins (11/15)
were significantly higher than those of wP-primed children.
The PT-specific IFN-, IL-17, and IL-10 as well as the Prn-
specific IL-10 were also higher in aP-primed children but did
not reach significance (Fig. 2).
In wP-primed children, the aP booster did enhance the pertus-
sis-specific TNF-, IFN-, and IL-5 production, an effect which
was significant for FHA- and Prn-specific IL-5 as well as the Prn-
specific IFN-. In contrast, the aP booster in aP-primed children
did not enhance the T-cell cytokine concentrations. Moreover,
after administration of a fifth high-dose aP vaccine, the FHA-
specific IFN- and IL-17 response even showed a decline. In gen-
eral, the pertussis-specific IL-17 and IL-10 values were low com-
pared with the other cytokine values, especially for PT (Fig. 2).
To compare the production levels of the Th2 cytokine and
the Th1 cytokines, the geometric mean values (GMs) of the
IL-5 levels per group before and after the booster were com-
pared to those of IFN-. The GM of the Th2 cytokine IL-5
specific for PT was about 6-fold higher in aP-primed children
than was the Th1 IFN- GM before booster vaccination. At 28
days after a fifth, high-dose aP vaccine, the IL-5 GM was about
10- to 20-fold higher than that of IFN- for all three pertussis
antigens. In contrast, similar values of Th1 and Th2 cytokines
were found in wP-primed children (Fig. 2).
Kinetics of the T-cell cytokine production in wP- and aP-
primed children after a preschool aP booster vaccination. To
illustrate the kinetics of the T-cell cytokine production after an aP
booster vaccination at 4 years of age, the concentrations of two
other cytokines are presented in Table 1, showing data for day 10
after an aP booster vaccination, too. Also, for the Th1 cytokine
IL-2 and the Th2 cytokine IL-13, prebooster T-cell cytokine levels
specific for all pertussis antigens were significantly higher in aP-
primed children than in wP-primed children, as shown for the
other cytokines (Table 1).
In general, the T-cell cytokine concentrations of wP-primed
children specific for all pertussis antigens showed increased values
already at day 10 after a low-dose booster vaccination. These val-
ues were significantly higher for FHA- and Prn-specific IL-2 as
well as PT- and Prn-specific IL-13. During the next 18 days, no
significant differences in cytokine production were observed. In
contrast, no increased values or a tendency toward lower values
was observed at day 10 after even a high-dose aP booster in aP-
primed children (Table 1).
Due to the high prebooster values, the IL-13 cytokine levels for
all three proteins in aP-primed children at day 28 after a low-dose
booster were still higher than those found in wP-primed children
after a low-dose booster vaccination. This was also found for PT-
specific IL-2 and IL-13 at 28 days after a high-dose booster, al-
though the differences were not significant due to the high varia-
tion in the relatively small amount of samples (Table 1).
Induction of IFN--producing T cells in wP- and aP-primed
children. The numbers of IFN--producing T cells in wP- and
aP-primed children before and at 10 and 28 days after the booster
showed the same pattern as that found for the cytokine values in
the T-cell supernatants. At 3 years after four aP vaccinations in the
first year of life, the numbers of IFN--producing cells specific for
all three pertussis antigenswere about 10-fold higher than those in
children vaccinated with wP in infancy (Fig. 3).
In wP-primed children, the numbers of IFN--producing cells
specific for PT increased significantly at both day 10 and day 28
after a low-dose booster (P 0.02 and P 0.04, respectively) as
well as after a high-dose booster (P 0.02). Those numbers spe-
cific for FHA and Prn were significantly increased at day 10 (P
0.04 and P 0.03, respectively) and were just slightly increased at
day 28 after either a low-dose or a high-dose booster. At day 28, a
high-dose booster in wP-primed children induced numbers of
IFN--producing cells comparable with those induced by a low-
dose booster for all three antigens (Fig. 3).
The already high numbers of IFN--producing cells at 4 years
of age prebooster in aP-primed children did not further increase
after children received either a low-dose or a high-dose booster.
Surprisingly, at 28 days after a high-dose aP booster vaccine, these
numbers even tended to decrease for all three antigens, which
resulted in significantly lower numbers (P  0.04) for Prn than
those after a low-dose booster (Fig. 3). Furthermore, at 28 days
after a low-dose preschool booster, the numbers of pertussis-spe-
cific IFN--producing cells in aP-primed children were higher
than those in wP-primed children, which reached significance for
TABLE 1 IL-2 and IL-13 produced by PBMCs of wP- and aP-primed children pre- and postbooster upon stimulation with PT, FHA, and Prna
Cytokine with
stimulant
Cytokine concn (pg/ml)
wP primed aP primed
Prebooster
(n 10)
10 days,
low dose
(n 8 or 9)
28 days,
low dose
(n 9)
28 days,
high dose
(n 8)
Prebooster
(n 9)
10 days,
high dose
(n 9)
28 days,
high dose
(n 6)
28 days,
low dose
IL-2
PT 0.01 () 0.04 (7.2) 1.5c (501) 0.05 (1.1) 7.0b (55.2) 3.0 (15.4) 19.6 (36.6) ND
FHA 0.01 () 0.6c (74.2) 6.0c (401) 1.6c (44.1) 36.1b (250) 22.5 (116) 37.9 (340) ND
Prn 0.01 () 0.1c (2.4) 0.5c (12.3) 0.3c (6.4) 10.6b (42.0) 5.1 (66.8) 7.1 (20.6) ND
(n 13) (n 10 or 11) (n 9 or 10) (n 8 or 9) (n 13) (n 11 or 12) (n 5 or 6) (n 5 to 7)
IL-13
PT 0.5 (28.4) 15.1c (143) 8.4 (111) 13.8c (443) 132b (3,877) 99.7 (948) 65.5 (255) 82.3 (693)
FHA 1.9 (79.0) 16.9 (267) 7.0 (152) 47.7c (230) 502b (7,322) 326 (2,754) 45.8 (799) 644 (1,543)
Prn 1.6 (45.1) 39.3c (174) 43.4c (157) 39.8c (212) 158b (450) 43.3 (999) 38.7 (270) 135 (148)
a Children 4 years of age were vaccinated with either a low-dose (Triaxis) or a high-dose (Infanrix) aP booster vaccine. Data are presented as geometric means (standard
deviations). ND, no data.
b Significantly higher prebooster values in aP-primed children than in wP-primed children.
c Significantly increased postbooster values compared to prebooster values in wP-primed children.
Schure et al.
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the antigens PT and FHA (P  0.04 and P  0.03, respectively)
and not just for Prn (P 0.06) (Fig. 3).
Correlations of cytokine levels. Significant correlations were
found for the concentrations of the Th2 cytokines IL-5 and IL-13
(R  0.81), for the Th1 cytokines IFN- and TNF- (R  0.45),
and even for the Th17 (IL-17) response with that of IFN- (R 
0.64) using the values (	10 pg/ml) of all wP- and aP-primed
children in this study (Fig. 4). Additionally, the correlations of the
Th1 cytokines IL-2, measured at 24 h, and IFN-, at day 5, were
similar (R  0.48). The correlation between Th1 and Th2 cyto-
kines mutually was lower (data not shown).
Differences in plasmapertussis-specific IgE levels ofwP- and
aP-primed children. In addition to pertussis-specific IgG levels
that were previously reported (6), we also evaluated pertussis-
specific IgE values upon the preschool booster vaccinations of 4
years old children. Pertussis-specific IgE values were similar in
wP- and aP-primed children before booster vaccination (Fig. 5).
Both PT- and Prn-specific IgE values increased after either a low-
dose or a high-dose booster vaccination in aP-primed and wP-
primed children (Fig. 5). However, in aP-primed children IgE
values specific for Prn were significantly higher after both booster
doses (P  0.01 and 0.0001, respectively) compared with wP-
primed children, and this was also the case for the IgE values
specific for PT after a high-dose booster (P  0.001). Total IgE
values were also higher in aP-primed children than in wP-primed
children after a low-dose or a high-dose booster vaccination (data
not shown).
DISCUSSION
We demonstrated that infant vaccinations with high-dose acellu-
lar pertussis vaccines resulted in high pertussis antigen-specific
Th1 and Th2 T-cell responses that persisted in children at least
until 4 years of age in aP-primed children, despite waning IgG
levels. Importantly, a fifth aP preschool booster vaccine at 4 years
of age did not show a typical memory response by increasing these
T-cell responses. In contrast, an aP booster inwP-primed children
did induce memory T-cell responses. Apart from inducing high
FIG 3 Numbers of IFN--producing cells prebooster and at 10 and 28 days
after booster vaccination in wP- (circles) and aP-primed (triangles) children
specific for the pertussis proteins PT, FHA, and Prn. At 4 years of age, bothwP-
and aP-primed children have been administered an aP booster with either a
low-dose (open symbols) or a high-dose (closed symbols) vaccine. Horizontal
lines indicate the geometric mean per group. #, significantly increased num-
bers postbooster compared to prebooster values in wP-primed children;
*, significantly increased numbers in aP-primed children compared to wP-
primed children; ‡, significantly higher numbers after a low-dose booster com-
pared to a high-dose booster in aP-primed children at 28 days postbooster.
FIG 4 Correlation of concentrations of the Th2 cytokines IL-5 and IL-13 (A),
the Th1 cytokines IFN- and TNF- (B), and the Th1 cytokine IFN- and the
Th17 cytokine IL-17 (C) present in T-cell culture supernatants of all wP- and
aP-primed children used in this study.
T-Cell Responses to Preschool aP Pertussis Vaccine
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IgG levels (13), the fifth aP vaccine elevated IgE antibody values,
which are associated with Th2 and atopic responses. Moreover,
pertussis-specific IgE values were increased in aP-primed children
after both low- and high-dose preschool booster vaccination.
Still, limited information on T-cell cytokine responses in
young children is available since most studies that evaluated pedi-
atric DTaP-IPV-Hib (HebB) and adult TdaP vaccines have fo-
cused on antibody responses against the different vaccine compo-
nents (13, 21, 24, 25). Pertussis-specific antibody levels found in
the 4-year-old children in this study (13) vaccinated at 2, 3, 4, and
11 months of age were comparable with data from French chil-
dren of the same age (12) vaccinated at 2, 4, and 18months of age.
In both countries, the prebooster anti-PT antibody levels were
similarly low in 4-year-old children and those specific for Prn and
FHA were higher after aP vaccination than those found after wP
vaccination (12, 13). The comparison of the few studies on cell-
mediated immune responses against pertussis and the replace-
ment of wP with aP vaccines is complicated since different vac-
cines, various vaccination schedules, and different age groups
have been used (1, 5, 12, 23, 32, 34). Similar Th1 responses have
been found before and 5weeks after the booster in 4- to 6-year-old
aP-primed children, whereas increased Th2 responses were found
after the fourth aP vaccination (34). However, we did not find
such an increase after a fifth aP booster vaccine. This discrepancy
probably results from the additional booster given after the pri-
mary series in the first year of life in our children, which might
explain the already higher levels of prebooster IL-5 at 4 years of
age. These IL-5 levels resemble the data of 4- to 6-year-old French
aP-vaccinated children, although their IFN- data were higher.
This can be explained by the comparison of mean values with
geometric mean values in combination with a high variation be-
tween samples. The higher cytokine levels in French wP-vacci-
nated children could have been induced by the use of a different
wP vaccine in France than the one used in The Netherlands (12).
The immunological basis of long-term vaccine-induced pro-
tection against pertussis is not clear yet. In the present study, we
determined pertussis-specific Th1, Th2, Th17, and T-regulatory
cytokine responses 3 years after infant aP or wP vaccinations but
also shortly after a preschool booster with two aP vaccines con-
taining different doses of proteins. After a fifth aP vaccination in
our study, the already high levels of all T-cell cytokines remained
elevated, whereas the IFN- levels and the numbers of IFN--
producing cells even slightly declined. The results for the IFN--
producing cells confirm the kinetics of the Th1 responses found in
T-cell supernatants, corroborating the differences in pre- and
postbooster T-cell responses between wP- and aP-primed chil-
dren. Surprisingly, we did not find a typical T-cell memory re-
sponse shown by an increase in cytokine production shortly after
a fifth high-dose aP vaccine. This might suggest that the T-cell
responses were still high enough to assist the T-cell-dependent
recall antibody production upon an aP booster in aP-primed chil-
dren, which has resulted in significantly increased postbooster an-
tibody levels (13). Althoughwewere not able to study the effects of
a high-dose aP booster in wP-primed children, we clearly showed
that even a low-dose aP booster vaccine did increase the post-
booster T-cell cytokine responses in these children at 10 days post-
booster. It can be expected that a high-dose aP booster vaccinewill
induce the same kinetics as those induced by a low-dose vaccine.
In aP-primed children, we did observe slightly higher Th2 re-
sponses than Th1 responses and low levels of IL-10 and IL-17
compared with the Th1 and Th2 cytokines. Although IL-17 plays
a role in protection against intracellular pathogens (10) and in
protection against Bordetella infection in mice (16), we do not
knowmuch about IL-17 induction in vaccinated children. In Eng-
lish infants vaccinated with Mycobacterium bovis BCG, also low
IL-17 and Il-10 levels were found, whereas in infants fromMalawi,
higher levels of these cytokines have been shown, suggesting that
this is influenced by the genetic background (20). In Bordetella
pertussis-infected adults, however, we didmeasure higher levels of
IL-17 (about 100 to 300 pg/ml) by using the same method as that
in the present study (36) (R.-M. Schure, K. O¨ztürk, L. de Rond, E.
A .M. Sanders, G. A.M. Berbers, and A.M. Buisman, unpublished
data). Anyway, the exact mechanism of T-cell responsiveness or
regulation in children is rather complex and needs to be the sub-
ject of further investigation.
After the fifth aP vaccination, at 4 years of age, the number of
children reporting various side effects has doubled in comparison
with that after an aP booster in wP-primed children. The local
adverse effects range from nontender redness (5 cm) to severe
swelling (	5 cm) at the injection site (18). Moreover, the aP-
primed children in this study showed increased pertussis-specific
IgE levels after both a low-dose and a high-dose booster vaccine.
This finding is in agreement with other studies (11, 34); however,
the clinical relevance of these increased IgE responses is not clear.
Since antihistamine was not effective in treating the adverse ef-
fects, the time course of these symptoms (mostly occurring within
1 or 2 days after vaccination [30]) reflects the possibility of a de-
layed-type hypersensitivity reaction caused by T cells and macro-
phages (29). We speculate that the four infant high-dose aP vac-
FIG 5 PT- (A) and Prn-specific (B) plasma IgE values in wP- (circles) and
aP-primed (triangles) children prebooster (n  46 and n  32, respectively)
and at 28 days after a low-dose booster (gray symbols) (n  46 and n  16,
respectively) or a high-dose booster (black symbols) (n  52 and n  35,
respectively). A horizontal line indicates the geometric mean per group.
*, significantly increased values postbooster compared to prebooster; #, signif-
icantly increased values in aP-primed children compared to wP-primed chil-
dren. MFI, mean fluorescence intensity.
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cinations might be responsible for the high prebooster Th1 and
Th2 responses. The preschool booster vaccination additive to on-
going T-cell immunity may explain the adverse local reactions,
which have been associatedwith Th2 responses by Rowe et al. (33)
and T-cell responses by Scheifele et al. (35). Further research is
necessary to assess the direct association between these high T-cell
responses and local side effects, and at the moment, a study that
recruits samples of children who actually report the local side ef-
fects is ongoing.
Our findings are in agreement with other studies (1, 23), show-
ing that memory T cells persist for years while antibody responses
wane rapidly after vaccination with aP or wP. This strongly sug-
gests that memory T cells might play an important role in pertus-
sis-specific long-term immunity. The T-cell responses in aP-
primed children can be induced by vaccination and natural
boosting due to the high circulation of pertussis in the population.
However, since wP-primed children showed much lower T-cell
responses than did aP-primed children of 4 years of age and the
incidence of pertussis during the inclusion period of both groups
was constant, the high T-cell responses were most likely induced
by the aP vaccines administered early in life. The immune system
of young infants is still under development and therefore very
sensitive to stimulation. We propose that the high doses of pro-
teins in the aP vaccines administered repeatedly within a short
period of time, at 2, 3, and 4 months of age followed by a booster
7 months later, initiate high T-cell responses, which are main-
tained till even 3 years later.
The aP priming in infancy in combination with a preschool aP
booster also induced high serum antibody levels (13) andmemory
B-cell responses (14). These responses togetherwith epidemiolog-
ical data indicate that protection against pertussis has improved in
children after replacing the Dutch wP vaccine with aP vaccines.
Since the effectiveness of vaccination is normally evaluated by
antibody levels alone, we would like to stress that monitoring T-
cell immunity in follow-up studies is necessary to better elucidate
the efficacy and safety of infant vaccines. Moreover, the aP vac-
cines contain not only purified proteins but also an adjuvant stim-
ulating the immune system to produce a Th2 response. In order to
improve the immune response induced by aP vaccines in the fu-
ture, the nature of the vaccine, the adjuvants, and the vaccination
intervals need to be reconsidered. A vaccination schedule of 2, 4,
and 6 months is employed by a third of the European countries
(euvac.net) but also by the United States, Canada, and the South
American countries. Therefore, we also recommend a more dis-
persed aP vaccination schedule starting at 2 months of age in The
Netherlands. A better understanding of T-cell responses and their
effect upon vaccination could result in a further improvement of
the pertussis vaccination schedules for infants. The improved
schedules should stimulate the immune system of infants in a
better way to protect against pertussis.
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